Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
May 27, 2016 09:29 ET
|
Intellipharmaceutics International Inc.
TORONTO, May 27, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
May 26, 2016 17:24 ET
|
Intellipharmaceutics International Inc.
TORONTO, May 26, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of...
Intellipharmaceutics Reports Director Election Results
April 19, 2016 17:30 ET
|
Intellipharmaceutics International Inc.
TORONTO, April 19, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces First Quarter 2016 Results
April 15, 2016 06:30 ET
|
Intellipharmaceutics International Inc.
TORONTO, April 15, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in...
Intellipharmaceutics to Present at the 28th Annual ROTH Conference
March 08, 2016 17:30 ET
|
Intellipharmaceutics International Inc.
TORONTO, March 08, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces 2015 Year End Results
February 26, 2016 21:45 ET
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 26, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Keppra XR®
February 24, 2016 22:03 ET
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics to Present at the Noble Financial Capital Markets’ 12th Annual Investor Conference
January 19, 2016 10:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista™ Oxycodone XR
January 14, 2016 07:30 ET
|
Intellipharmaceutics International Inc.
TORONTO, Jan. 14, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics to Present at the Biotech Showcase™
December 21, 2015 15:15 ET
|
Intellipharmaceutics International Inc.
TORONTO, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...